Browse > Article
http://dx.doi.org/10.14316/pmp.2015.26.4.229

Response Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer  

Choi, Ji Hoon (Department of Radiation Oncology, Kosin University Gospel Hospital, Kosin University College of Medicine)
Publication Information
Progress in Medical Physics / v.26, no.4, 2015 , pp. 229-233 More about this Journal
Abstract
We retrospectively reviewed lung cancer patients who were treated with stereotactic ablative radiotherapy (SABR). We investigated the value of response evaluation after treatment by measuring the volume change of tumors on serial chest computed tomography (CT) examinations. The study included 11 consecutive patients with early-stage (T1-T2aN0M0) non-small cell lung cancer (NSCLC) who were treated with SABR. The median dose of SABR was 6,000 cGy (range 5,000~6,400) in five fractions. Sequential follow-up was performed with chest CT scans. Median follow-up time was 28 months. Radiologic measurement was performed on 51 CT scans with a median of 3 CT scans per patient. The median time to partial response ($T_{PR}$) was 3 months and median time to complete remission ($T_{CR}$) was 5 months. Overall response rate was 90.9% (10/11). Five patients had complete remission, five had partial response, and one patient developed progressive disease without response. On follow-up, three patients (27.2%) developed progressive disease after treatment. We evaluated the the response after SABR. Our data also showed the timing of response after SABR.
Keywords
Lung cancer; Stereotactic ablative radiotherapy; SABR; SBRT;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shimkin MB, Connelly RR, Marcus SC, et al: Pneumonectomy and lobectomy in bronchogenic carcinoma. A comparison of end results of the Overholt and Ochsner clinics. J Thorac Cardiovasc Surg 44:503-19, 1962
2 Onishi H, Araki T, Shirato H, et al: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101:1623-31, 2004   DOI
3 Lagerwaard FJ, Haasbeek CJ, Smit EF, et al: Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685-92, 2008   DOI
4 Chang JY, Liu H, Balter P, et al: Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7:152, 2012   DOI
5 Crabtree TD, Denlinger CE, Meyers BF, et al: Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 140: 377-86, 2010   DOI
6 Iyengar P, Westover K, Timmerman RD: Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer. Semin Respir Crit Care Med 34:845-54, 2013   DOI
7 Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al: Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 83:348-53, 2012   DOI
8 Onishi H, Shirato H, Nagata Y, et al: Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352-8, 2011   DOI
9 Palma D, Visser O, Lagerwaard FJ, et al: Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 101:240-4, 2011   DOI
10 Shirvani SM, Jiang J, Chang JY, et al: Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 149:1244-53, 2014   DOI
11 Taremi M, Hope A, Dahele M, et al: Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 82:967-73, 2012   DOI
12 Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-6, 2010   DOI
13 Verstegen NE, Oosterhuis JW, Palma DA, et al: Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity scorematched analysis. Ann Oncol 24:1543-8, 2013   DOI
14 Palma D, Visser O, Lagerwaard FJ, et al: Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based timetrend analysis. J Clin Oncol 28:5153-9, 2010   DOI
15 De Rose F, Cozzi L, Navarria P, et al: Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clin Oncol (R Coll Radiol), 2015
16 Chang JY, Senan S, Paul MA, et al: Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-smallcell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630-7, 2015   DOI
17 Heal C, Ding W, Lamond J, et al: Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting. Front Oncol 5:146, 2015
18 Force J, Rajan A, Dombi E, et al: Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. J Thorac Oncol 6:1267-73, 2011   DOI
19 Chaudhuri AA, Tang C, Binkley MS, et al: Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 89:50-6, 2015   DOI
20 Shah GD, Kesari S, Xu R, et al: Comparison of linear and volumetric criteria in assessing tumor response in adult highgrade gliomas. Neuro Oncol 8:38-46, 2006   DOI